Reaction

Skin Erosion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,152 reports · 66 co-occurring drugs

As of the last recalculation, Skin Erosion appears in 3,152 FAERS reports alongside 66 co-occurring drug terms. The strongest observed disproportionality signal is SULFUR (PRR 12.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sulfur	16	12.6	12.6
Febuxostat Tablets 40 Mg	18	11.7	11.8
Febuxostat Tablets 80 Mg	18	11.7	11.8
Nebivolol	25	10.4	10.5
Captopril	14	9.7	9.7
Cabozantinib	63	8.8	8.8
Imatinib	23	8.7	8.7
Clobetasol Propionate Ointment Usp, 0.05%	12	7.7	7.7
Clobetasol Propionate	12	7.7	7.7
Crisaborole	11	7.6	7.6
Miconazole Nitrate	10	7.6	7.6
Felodipine Extended-Release Tablets	13	7.6	7.6
Felodipine	13	7.6	7.6
Tretinoin	9	7.3	7.3
Febuxostat	18	7.1	7.1
Terbinafine Hydrochloride	9	6.7	6.7
Sirolimus	13	6.4	6.4
Mupirocin	13	6.4	6.4
Lamotrigine	123	6.4	6.4
Mupirocin Calcium	13	6.3	6.3
Carbamazepine	60	6.0	6.0
Panitumumab	14	5.9	5.9
Piperacillin And Tazobactam	11	5.7	5.7
Triamcinolone Acetonide Ointment Usp, 0.05%	20	5.7	5.7
Thiotepa	8	5.5	5.5
Cefazolin Sodium	10	5.5	5.5
Nebivolol Hydrochloride	27	5.3	5.3
Adapalene	127	4.8	4.8
Triamcinolone Acetonide	22	4.7	4.7
Regorafenib	8	4.6	4.6
Dupilumab	307	4.6	4.6
Apalutamide	8	4.5	4.5
Piperacillin Sodium,Tazobactam Sodium	18	4.5	4.5
Tranexamic Acid	6	4.5	4.5
Erlotinib Hydrochloride	8	4.2	4.2
Pyrazinamide	6	4.2	4.2
Loperamide Hcl	8	4.1	4.1
Pembrolizumab	62	3.9	4.0
Salicylic Acid	31	3.9	3.9
Micafungin Sodium	5	3.9	3.9
Loperamide Hydrochloride Oral	6	3.9	3.9
Pitavastatin Calcium	6	3.9	3.9
Bendamustine Hydrochloride	7	3.9	3.9
Axitinib	11	3.7	3.7
Pertuzumab	15	3.7	3.7
Nemolizumab-Ilto	7	3.6	3.6
Fludarabine Phosphate	21	3.5	3.5
Tiotropium Bromide Inhalation Spray	6	3.5	3.5
Sorafenib	11	3.5	3.5
Gefitinib	4	2.9	2.9
Pemetrexed	9	2.8	2.8
Tolvaptan	6	2.7	2.7
Erlotinib	4	2.7	2.7
Docetaxel Anhydrous	27	2.7	2.7
Docetaxel	27	2.7	2.7
Secukinumab	62	2.6	2.6
Lapatinib	6	2.6	2.6
Ranolazine	4	2.5	2.5
Risankizumab-Rzaa	31	2.5	2.5
Pemetrexed Disodium	14	2.4	2.4
Diclofenac Potassium, Film Coated	3	2.4	2.4
Diclofenac Potassium Tablets	3	2.4	2.4
Rimegepant Sulfate	4	2.1	2.1
Nivolumab	30	2.1	2.1
Etonogestrel	10	1.4	1.4
Ixekizumab	7	1.2	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.